Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route
|
|
- Scarlett Craig
- 6 years ago
- Views:
Transcription
1 Aurum Equity Partners LLP Aurum Insights Pharmaceuticals October 2014 Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route Read more of the M&A action in this issue Read online on
2 Indian Pharma companies are aggressively building out a global franchise through increased M&A and Collaboration route Gautam Dhawan Partner, Aurum Equity Partners LLP Global Generics Market is favorably positioned The global generics market is expected to grow from USD 240 bn in 2011 to USD 400 bn in 2016 representing a CAGR of 11%. This growth is being driven by : Unsustainable Healthcare Costs in Developed Markets Rising Healthcare costs are driving Governments to implement pro-generic policies e.g. US Health Insurance reforms, EU5 to shift usage to Generic and Promotion of generic drugs in Japan Payer-funding models shift towards outcomes and lower costs Increased demand in Emerging Markets > 70% of the growth is expected to be driven by key markets- China, India, Latin America Key drivers are rising income levels, insurance penetration levels and greater Government role in providing healthcare Brand V/s Generic Drug Growth Trajectory % 36% 12% Brand Generic % 27% 12% Other. Total medicine spending will increase from USD 965 bn in 2012 to 1,200 bn in 2017 representing a CAGR of 4.5%. Generics share will increase from 26% in 2012 to 36% in 2017 led by a progeneric environment, rising generic utilization and patent expiries. Private and Confidential For Limited Circulation Only 2
3 Indian Domestic Market facing short term headwinds The Indian domestic market is pegged at USD 13 bn (2011) and growing at a CAGR of 15%. While the long term outlook is intact, there are short term headwinds like new drug pricing policy which could impact growth of Indian Companies in the domestic market Indian Pharma Industry Revenue (INR bn) Year on Year Change % International Markets represent a large and growing opportunity In order to drive growth, Indian companies are focusing on developed markets (especially the U.S.) and emerging countries wherein the size of the opportunity is much higher. Emerging Markets (EM s) The Next Growth Driver Pharmaceutical spending to increase from US$190bn in 2011 to US$360bn by 2016 representing a CAGR of 15% EM s present an ideal fit given their branded generic characteristic similar to India Many Indian companies have entered these markets through the inorganic route US Market Niche Opportunities Rising generic penetration levels 50% of the expiries are in the limited competition segment - respiratory, transdermal patches, controlled substances etc Large Indian companies have invested heavily in terms of R&D, filings, manufacturing and front- end presence While India continues to be a strategic market, Indian companies are aggressively expanding overseas through a combination of organic, inorganic and collaboration route. A slew of deals announced in the past few months exemplifies this growth strategy. Private and Confidential For Limited Circulation Only 3
4 Globally the Pharma Generic Market is consolidating Global Pharma companies have been consolidating over the past many years. Mylan, Actavis, Teva, Aspen, Sun Pharma have been growing through a series of acquisitions. The key driver is to build a global franchise through scale in products, R&D, manufacturing and technology. USD 25 bn acquisition of US based Forest Laboratories by Actavis. This deal is partly designed to position the resulting company to deal with the changing health-care landscape in the U.S. The combined company is expected to have more than $15 billion in revenue for 2015, and the deal is expected to immediately add to adjusted earnings, with double-digit accretion in 2015 and 2016 Niche pharmaceutical company Akorn Inc completed its acquisition of Hi Tech Pharmacal Co for USD 640 mn in an all cash transaction. This deal is expected to provide Akorn with additional breadth in the retail OTC market, help diversify its revenue base and strengthen its R&D pipeline. Mylan entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott's non- U.S. developed markets specialty and branded generics business in an all-stock transaction. The all stock deal is valued at USD 5.3 bn. Indian Companies are likely to remain at the M&A forefront given their strong balance sheet, Free cash flow generation and desire to grow internationally Broadly, acquisitions by Indian companies have been focused on the following: Acquiring technological capabilities in some of the complex therapy areas Filling portfolio gaps Strengthening presence in some of the fast-growing emerging markets The above trend is visible in a string of M&A / partnership deals that have taken place in the last 6 to 12 months. Companies including Cipla, Sun Pharma, Aurobindo and Lupin have inked deals to expand their presence globally In the past Indian companies have adopted a more conservative approach towards M&A pursuing smaller companies with reasonable valuations. However, we believe that given huge set of opportunities and the need to build capabilities in areas like biosimilars, OTC, specialty pharma or new market access, larger deals cannot be ruled out. Private and Confidential For Limited Circulation Only 4
5 Table 1: Select Recent Transactions in the Pharma Sector Date Deal Type Company Target/ Partner Deal Size (USD mn) 29/10/2014 M&A Strides Arcolabs Shasun Pharma /09/2014 Licensing Cipla Gilead Sciences NA 09/09/2014 Private Equity Apax Partners LLP Strides Acrolab 8 12/06/2014 Acquisition Meiji Seika Medreich /05/2014 Private Equity KKR Gland Pharma Limited /04/2014 Merger Sun Pharmaceutical Ranbaxy Laboratories 4,000 01/04/2014 Acquisition Aurobindo Pharma Western European Businesses of Actavis 40 28/03/2014 Acquisition Lupin Limited Grin Laboratorios NA 13/12/2013 Acquisition Torrent Pharmaceuticals Elder Pharma, Formulation Business /10/2013 Private Equity CX Partners Natco Pharma 17 15/03/2013 Acquisition Fresenius Kabi Parenteral Drugs, Goa Manufacturing Unit 37 01/03/2013 Acquisition Mylan Agila Specialties 1,750 23/01/2013 Private Equity Tata Healthcare Marck Biosciences 40 Private and Confidential For Limited Circulation Only 5
6 Private and Confidential For Limited Circulation Only 6 The Aurum Perspective on select transactions - In September 2014, Cipla signed a licensing agreement with Gilead Sciences for manufacturing and distribution of Sofosbuvir mono, Ledipasvir mono and the fixed-dose combination of Ledipasvir/Sofosbuvir, for the treatment of Hepatitis C. Cipla will manufacture and market products in 91 countries including home markets India and South Africa under Cipla s own brand names Under the licensing agreements, Cipla will receive technology transfer from Gilead to enable them to scale up production quickly Aurum Perspective The collaboration provides Cipla with Gileads s path breaking technology to serve nearly 100 million people living with Hepatitis C globally, representing 54% of total global infected population. For Cipla this is a unique collaboration a) Agreement provides access to a large target market b) leveraging its vast manufacturing capabilities to sell the drug at competitive prices c) leveraging its front end presence in many markets and d) provides a fillip to Cipla s ongoing commitment to provide innovative medicines to patients This deal will enhance Cipla s revenue and earning potential over the next few years.
7 The Aurum Perspective on select transactions - In March 2014, Lupin Limited acquired 100% equity stake in Laboratorios Grin, S.A. De C.V.(Grin), the fourth largest pharmaceutical company in Mexico in the eye care segment Grin is a specialty pharmaceutical company engaged in the development, manufacturing & commercialization of branded Ophthalmic products. It is the fourth largest pharma company in Mexico in the high growth eye care segment with revenues close to USD 30 mn. The Mexican ophthalmic market is currently valued at $ 275 Mn and has grown at close to 10% over the last 5 years. It is expected to reach $ 450 Mn by Aurum Perspective This acquisition will help Lupin foray into the large and fast growing Mexican market and subsequently expand in the larger Latin American pharmaceuticals market. The acquisition provides Lupin with a) new market access b) access to the ophthalmology segment and drive synergies through their pipeline and c) leveraging Grin s platform to expand into other high growth segments Private and Confidential For Limited Circulation Only 7
8 The Aurum Perspective on select transactions - In April 2014, Aurobindo Pharma acquired few key Western European businesses of Actavis Aurobindo Pharma acquired personnel, commercial infrastructure, products, marketing authorizations and dossier license rights of Actavis in seven European countries. The acquisition will enable Aurobindo to achieve critical mass in Western Europe with a top 10 position in several key markets. The acquired business has revenues of USD 435 mn and EBITDA loss of USD 40 mn. For Aurobindo, the acquisition is at virtually zero cash outgo as deal value of USD 40 mn also includes net current assets in excess of USD 40 mn Aurum Perspective Aurobindo's acquisition of commercial operations in 7 European Countries is a good example of leveraging inherent strengths to gain ready access to major geographies. In this deal Aurobindo has also entered into a larger supply agreement with Actavis which will provide enhanced capacity utilization of its manufacturing. This model could be emulated by other mid-sized Indian Players by looking at similar arrangements with top Generic Players. This deal will enhance Aurobindo s revenues in the Europe operations and given the strong India-based manufacturing set-up, it would be able to improve EBITDA margin going forward. However, site-transfer and cost optimization may take a few years before profit visibility. Private and Confidential For Limited Circulation Only 8
9 The Aurum Perspective on select transactions In April 2014, Sun Pharmaceutical announced an acquisition of Ranbaxy Laboratories for USD 4 bn; Approx 2.2x sales Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. Daichii Sankyo the parent company of Ranbaxy will now hold a 9% stake in Sun Pharma as a result of its stake in Ranbaxy. Aurum Perspective This transaction is a transformational deal for Sun Pharma as it creates the 5 th largest global specialty company: # 1 pharma company in India # 1 Indian pharma company in the US market with a strong pipeline Bigger presence in emerging and Western European markets This transaction exemplifies Sun Pharma s desire to expand their business globally through M&A route and strong track record of turning around companies. Private and Confidential For Limited Circulation Only 9
10 ). The Aurum Perspective on select transactions In December 2013, Mylan Inc. completed the acquisition of the Agila s injectables business from Strides Arcolab Limited for up to $1.75 billion, which includes $250 million in contingent consideration Agila is a Unique, global pure-play injectables platform operating across liquid injectables, lyophilized injectables, oncology and ophthalmic and other forms (PFS, oral, dry powder). Enterprise Value 7.5x Sales and 22x EBITDA Aurum Perspective The acquisition of Agila will make Mylan a global injectables leader, expanding and strengthening its existing injectables platform and portfolio, and providing it entry into new geographic markets. The combination strengthens Mylan's existing platform in developed markets, such as the U.S., where Mylan can now offer customers an even more comprehensive portfolio of high quality products, The acquisition will also help Mylan accelerate its expansion into key rest-of-world markets, including Brazil, India and Southeast Asia. Agila will bring a broad product portfolio of more than 300 filings approved globally and marketed through a network covering 70 countries, including 61 abbreviated new drug applications (ANDAs) approved by the US Food and Drug Administration (USFDA) Private and Confidential For Limited Circulation Only 10
11 Concluding notes The prospects of the Global generics market are looking bright over the next few years, given the pro-generic environment in developed markets, rising utilization levels, patent expiries and growing Government role in providing healthcare in emerging markets. As a result, Generics share in total medicine spending will rise to 37% by 2017 and the branded segment will fall to 52% during the same period. This augurs well for the Indian Generic industry which has been growing steadily over the past few years. While the Indian domestic market has grown at a CAGR of 15% over the past 5 years, there are initial signs of a slowdown. However, we believe this is transient in nature and long-term growth drivers remain intact. Most industry participants believe that the long term growth stands at 14-15%. The overseas markets represent a large opportunity and many Indian companies like Sun, Lupin, Cipla, Zydus, Torrent have been expanding their presence over the past few years. While the US is clearly the biggest market the opportunity there is becoming more niche injectables, respiratory, ophthalmics, dermatalogy, transdermal patches etc and companies will have to focus in building a pipeline in these segments. On the other hand, Emerging Markets will double spending over the next few years and offers meaningful opportunities. While Indian companies have sizable scale in terms of revenue, they lag far behind the global generics when it comes to inorganic growth. With low leverage and strong free cash flow generation over the next few years, some of them are likely to turn more aggressive in pursuit of growth. Further, sizable promoter holdings across companies provide another potential source of funds and enhance companies ability to raise debt. Two key factors driving inorganic initiatives would be (1) market access and (2) technology or portfolio enhancements. The recent deals over the past 6-12 months does indicate Indian Pharma companies aggressive plans to build a global pharma franchise and we expect many more Indian companies to emerge as global leaders in the fast growing generic market. For more details, write to Gautam Dhawan at gautamdhawan@aurumequity.com
12 Aurum was established, as a mid-market focused; transaction oriented; investment banking firm, by a team of professionals with decades of experience in investment banking, private equity and general management. Aurum advises clients on M&A, Divestitures, Fund Raising and Restructuring, focusing on sectors that are in the high-growth trajectory. The Aurum team s experience in handling large and complex transactions helps in accelerating the speed of response that the Client needs to demonstrate, in order to close transactions in a competitive environment. We have the ability to structure deals derived from understanding the client's strengths and constraints, further enabled by understanding of market trends and relevant regulatory environment. For any further queries and information, please write to us at ritikasingh@aurumequity.com Disclaimer: This report is presented solely for the internal use of the recipient to whom it is marked by Aurum Equity Partners LLP ( Aurum ) and does not carry any right of publication or disclosure to any other party. This report has been prepared on the basis of information obtained from publicly available, accessible resources. Aurum has not independently verified all the information given in this report. Neither Aurum nor its affiliates, partners, directors, employees, agents or representatives, shall be responsible or liable in any manner, directly or indirectly, for the contents or any errors or discrepancies herein or for any decisions or actions taken in reliance on the report. 12
Bird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationWarm Welcome Shareholders. 22nd Annual General Meeting June 10, 2013
Warm Welcome Shareholders 22nd Annual General Meeting June 10, 2013 Performance Snapshot - FY 2012 Revenue * EBITDA * 31% 36% 2291 INR Crores (Except EPS) 562 1748 413 904 920 1188 104 159 320 2008 2009
More informationIndian Active Pharmaceutical Ingredients (APIs) Industry Report,
Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 608.85 Target Price 694.00 CIPLA LIMITED Result Update (PARENT BASIS): Q2 FY15 NOVEMBER 18 th,2014 ISIN: INE059A01026 Index Details Stock Data Sector Pharmaceuticals BSE Code 500087 Face Value
More informationIndian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
More informationMergers & Acquisitions
Mergers & Acquisitions Shailesh Haribhakti 22 nd February, 2014 Overview of global M&A deals Global M&A activity in 2013 was flat (USD 2.22 trillion vs. USD 2.29 trillion in 2012). However H2 was relatively
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationFrank Staud, Executive Vice President, Watson to Acquire Actavis Group for EUR4.25 Billion
NEWS RELEASE WATSON CONTACTS: ACTAVIS CONTACT: Investors: Frank Staud, Executive Vice President, Lisa Defrancesco Corporate Communications (862) 261-7152 41 41 462 7370 Patty Eisenhaur (862) 261-8141 Media:
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationAccelerating our IPT strategy
Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based
More informationQ4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017
Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationInvestor Presentation
Aurobindo Pharma Limited Investor Presentation Investor Presentation August 2015 May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect
More informationDear Fellow Shareholders On behalf of the Board of Directors, I take pleasure in welcoming all of you to the 17 th AGM of your company.
Text of the speech delivered by Mr. Dilip Shanghvi, Chairman and Managing Director of the Sun Pharmaceutical Industries Ltd., at the 17 th Annual general meeting of the company held on Sept 11, 2009 in
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationInvestor Relations Presentation. Delivering solutions, shaping the future
Investor Relations Presentation Delivering solutions, shaping the future Our Story Leader Differentiator Consistency Decades of experience Leading the dispensing solutions niche of the packaging industry
More informationCadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)
2QFY2013 Result Update Pharmaceutical November 7, 2012 Cadila Healthcare Performance Highlights ACCUMULATE CMP 860 Target Price 926 Y/E March (` cr) 2QFY2013 1QFY2013 % chg (qoq) 2QFY2012 % chg (yoy) Investment
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationINVESTOR PRESENTATION. November 2015
INVESTOR PRESENTATION November 2015 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the implementation
More informationEndo Health Solutions
Endo Health Solutions 3Q 2013 Earnings Report and A Compelling Combination: Endo Health Solutions and Paladin Labs November 5, 2013 Offer Language Disclosures This communication is not intended to and
More informationCatalent, Inc. Jefferies Global Healthcare Conference. June 9, DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.
Catalent, Inc. Jefferies Global Healthcare Conference June 9, 2016 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied. Disclaimer Statement Forward-Looking Statements This
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationAurobindo Pharma Limited. Investor Presentation
Aurobindo Pharma Limited Investor Presentation May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation, statements
More informationInvestor Presentation
Investor Presentation Q3 FY 15 Earnings Release 12 Feb 2015 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute
More informationViews on the Generics Market
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul, Turkey 15 th June 2007 Safe Harbor Except for
More informationMylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
November 6, Mylan Reports Third Quarter Results and Updates Guidance HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationGeneric Medicine in South Africa Past, Present and Future. 15 th Annual IGPA Conference 2012 Kyoto - Japan. Dr. Fathima Docrat Chief Executive Officer
Generic Medicine in South Africa Past, Present and Future 15 th Annual IGPA Conference 2012 Kyoto - Japan The National Association of Pharmaceutical Manufacturers (NAPM), is a voluntary, nonprofit organization
More informationRegulatory Statements
Vision2020 Regulatory Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of federal securities laws. These statements are subject to a variety
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationStrides Arcolab. CMP: INR717 TP: INR829 Buy
BSE SENSEX S&P CNX 17,144 5,200 Bloomberg STR IN Equity Shares (m) 57.7 52-Week Range (INR) 794/276 1,6,12 Rel. Perf. (%) -2/37/98 M.Cap. (INR b) 41.4 M.Cap. (USD b) 0.7 31 July 2012 2QCY12 Results Update
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference John J. Greisch, President and CEO January 9, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform
More informationAkorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of $10.6 million- -Raises Outlook for 2011-
At the Company: Akorn, Inc. Tim Dick, Chief Financial Officer (847) 279-6150 FOR IMMEDIATE RELEASE Akorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of
More informationPolyOne Investor Presentation KeyBanc 2014 Basic Materials & Packaging Conference Boston, MA September 10, 2014
PolyOne Investor Presentation KeyBanc 2014 Basic Materials & Packaging Conference Boston, MA September 10, 2014 PolyOne Corporation Page 1 Forward-Looking Statements In this presentation, statements that
More informationCroda International Plc 2015 Full Year Results
Croda International Plc 2015 Full Year Results 23 February 2016 Cautionary statement This review is intended to focus on matters which are relevant to the interests of shareholders in the Company. The
More informationFinancial Predictors Influencing the Ranking of Indian Pharmaceutical Companies 2016
International Journal of Accounting, Finance and Risk Management 2016; 1(1): 39-45 http://www.sciencepublishinggroup.com/j/ijafrm doi: 10.11648/j.ijafrm.20160101.16 Financial Predictors Influencing the
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationQ4 FY17-18 EARNINGS PRESENTATION
Q4 FY17-18 EARNINGS PRESENTATION 28 th May 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationMeda to acquire Rottapharm Madaus, creating a European specialty pharma leader
Meda to acquire Rottapharm Madaus, creating a European specialty pharma leader 31 July, 2014 Dr. Jörg-Thomas Dierks, CEO Henrik Stenqvist, CFO 1 Disclaimer Forward-looking statements Except for the historical
More informationEndo Health Solutions
Endo Health Solutions 4Q 2013 Earnings Report and Announcing The New Endo February 28, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationInvestor Presentation Q2FY
Investor Presentation Q2FY19 05-11-2018 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation July-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationWaters Corporation Management Presentation. July 2018
Waters Corporation Management Presentation July 2018 Cautionary Statements This presentation may contain forward-looking statements regarding future results and events. For this purpose, any statements
More informationAcquisition of Altamira Creating the undisputed leader in NPL and REO servicing in Southern Europe. January 8, 2019
Acquisition of Altamira Creating the undisputed leader in NPL and REO servicing in Southern Europe January 8, 2019 Strategic Highlights of a Landmark Acquisition for dobank Altamira Asset Management Leading
More informationMylan Q EARNINGS November 5, Q Earnings All Results are Unaudited
Mylan Q3 EARNINGS November 5, Q3 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to the safe harbor
More informationBUY AJANTA PHARMA LTD. CMP Target Price JAN. 28 th 2014 SYNOPSIS. Result Update: Q3 FY14
BUY CMP 940.00 Target Price 1025.00 AJANTA PHARMA LTD. Result Update: Q3 FY14 JAN. 28 th 2014 ISIN: INE031B01031 Index Details Stock Data Sector Pharmaceutical BSE Code 532331 Face Value 5.00 52wk. High
More informationStericycle Investor Presentation Q NASDAQ: SRCL
Stericycle Investor Presentation Q3-2017 NASDAQ: SRCL Forward - Looking Statements Safe Harbor Statement: This press release may contain forward-looking statements that involve risks and uncertainties,
More informationPharmaceutical Industry
Intra Legem July 2, 2016 Pharmaceutical Industry Globally, the India Pharmaceutical Industry ranks 3 rd in terms of volume and 14 th in terms of value 1. Branded generics dominate the pharmaceuticals market,
More information2016 THIRD-QUARTER EARNINGS REVIEW October 25, 2016
2016 THIRD-QUARTER EARNINGS REVIEW October 25, 2016 0 THIRD-QUARTER EARNINGS PRESENTATION WHIRLPOOL CORPORATION ADDITIONAL INFORMATION This presentation contains forward-looking statements about Whirlpool
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationQ2 FY18-19 EARNINGS PRESENTATION
Q2 FY18-19 EARNINGS PRESENTATION 12 th November 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationHill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016
Hill-Rom Fourth Quarter 2016 Financial Results November 3, 2016 Forward Looking Statements Certain statements in this presentation contain forward-looking statements, within the meaning of the Private
More informationAlembic Pharmaceuticals Ltd. Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation October-2016 Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials
More informationPress Release. Consolidated Financial & Performance Highlights (Pharma & Biotech)
Press Release Strides Shasun announces Q1 FY17 results Q1 FY17 Pharma Revenues* at INR 8,699 Mn, Growth of 43% YoY, Pharma EBITDA at INR 1,451 Mn, Growth of 57% YoY Bengaluru, August 17, 2016: Strides
More informationJEFFERIES GLOBAL HEALTHCARE CONFERENCE
JEFFERIES GLOBAL HEALTHCARE CONFERENCE November 20, 2014 2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section
More information36 th Annual J.P. Morgan Healthcare Conference. January 8, 2018
36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements
More informationQ3 FY17-18 EARNINGS PRESENTATION. 7 th February 2018
Q3 FY17-18 EARNINGS PRESENTATION 7 th February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationDelivering Solutions. Shaping the Future.
Delivering Solutions. Shaping the Future. August 2014 Forward-Looking Statements This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions
More informationDepartment of Industrial Policy and Promotion. Department of. Pharmaceuticals. Pharmaceuticals. Sector. Achievements Report MAKE IN INDIA
1 Department of Industrial Policy and Promotion Department of Pharmaceuticals Pharmaceuticals Sector Achievements Report January 18, 2017 MAKE IN INDIA Table of Contents 03 Policy Initiatives & Investments
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationJefferies 2017 Health Care Conference
Jefferies 2017 Health Care Conference New York June 2017 Forward Looking Statements This presentation contains, and answers given to questions that may be asked today may constitute, forward-looking statements
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationHardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy
BSE Sensex S&P CNX 19,990 6,069 Bloomberg LPC IN Equity Shares (m) 447.6 M.Cap. (INR b)/(usd b) 324.5/6.0 52-Week Range (INR) 739/507 1,6,12 Rel. Perf. (%) 9/18/13 Financials & Valuation (INR b) Y/E March
More informationGerresheimer A Leading Partner for the Pharma & Life Science Industry. Eigenkapitalforum Deutsche Börse AG. Frankfurt, November 11, 2008
Gerresheimer A Leading Partner for the Pharma & Life Science Industry Eigenkapitalforum Deutsche Börse AG Frankfurt, November 11, 2008 Hans-Jürgen Wiecha, CFO 0 Disclaimer This presentation may contain
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationSPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS
SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS The rising cost of drugs, fuelled by the growing specialty
More informationPART I STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2015
PART I STATEMENT OF CONSOLIDATED RESULTS Rs. in Lakhs Sl. No. Year to date figures for the current year ended Previous period (1) (2) A) Continuing operations: 1 Income from operations (a) Net Sales /
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationJ.P. Morgan Diversified Industrials Conference. Dave Anderson Senior Vice President and CFO
J.P. Morgan Diversified Industrials Conference 0 Dave Anderson Senior Vice President and CFO Forward Looking Statements This report contains forward-looking statements within the meaning of Section 21E
More informationQ2 and financial outlook. Simon Dingemans, CFO
Q2 and financial outlook Simon Dingemans, CFO Headline results Continued sales growth and investment in the future Q2 2017 Reported growth % H1 2017 Reported growth % m AER CER m AER CER Turnover 7,320
More informationSeptember 11, Corporate Update. Rich Tobin, President & Chief Executive Officer
September 11, 2018 Corporate Update Rich Tobin, President & Chief Executive Officer Forward-Looking Statements and Non-GAAP Measures Our comments may contain forward-looking statements that are inherently
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationInvestor Relations Presentation
Investor Relations Presentation Delivering solutions, shaping the future. Beauty + Home Food + Beverage Pharma Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationUnilever Investor Event 2018 Graeme Pitkethly 4 th December 2018
Unilever Investor Event 2018 Graeme Pitkethly 4 th December 2018 SAFE HARBOUR STATEMENT This announcement may contain forward-looking statements, including forward-looking statements within the meaning
More informationSanofi India. CMP: INR2,200 TP: INR1,848 Neutral
BSE SENSEX S&P CNX 16,846 5,110 Bloomberg SANL IN Equity Shares (m) 23.0 52-Week Range (INR) 2,430/1,980 1,6,12 Rel. Perf. (%) 3/-3/15 M.Cap. (INR b) 50.7 M.Cap. (USD b) 0.9 26 July 2012 2QCY12 Results
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More informationCase M TEVA/ALLERGAN GENERICS
EUROPEAN COMMISSION DG Competition Case M. 7746 TEVA/ALLERGAN GENERICS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Decision on the implementation of remedies
More informationInvestor Day April 2010 INVESTMENT STRATEGY. Mr. DAVID DIAZ Corporate Development Director
Investor Day April 2010 INVESTMENT STRATEGY Mr. DAVID DIAZ Corporate Development Director abertis: Investment strategy 1. An overview of the infrastructure market 2. abertis strategy 3. A robust methodology
More informationHello and welcome to this discussion of GSK s first quarter results for 2015.
GSK Simon Dingemans Hello and welcome to this discussion of GSK s first quarter results for 2015. We have issued a press release today setting out in detail our views of the prospects for the Group now
More informationGUFIC MANAGEMENT DISCUSSION AND ANALYSIS
GUFIC BIOSCIENCES LIMITED MANAGEMENT DISCUSSION AND ANALYSIS Indian Pharma Industry an overview The Indian Pharmaceutical industry has been witnessing phenomenal growth in recent years, driven by rising
More informationSun Pharma BUY. Performance Highlights. `783 Target Price `944 CMP. 1QFY2017 Result Update Pharmaceutical. Investment Period 12 months
1QFY2017 Result Update Pharmaceutical August 17, 2016 Sun Pharma Performance Highlights (` cr) 1QFY2017 4QFY2016 % chg QoQ 1QFY2016 % chg yoy Net sales 8,007 7,414 8.0 6,527 22.7 Other income 393 185 112.3
More informationPolyOne Investor Presentation Credit Suisse Boston Basic Materials Conference. June 26, 2013
PolyOne Investor Presentation Credit Suisse Boston Basic Materials Conference June 26, 2013 Forward Looking Statements In this presentation, statements that are not reported financial results or other
More informationSun Pharma BUY. Performance Highlights. `683 Target Price `847 CMP. 2QFY2017 Result Update Pharmaceutical. Investment Period 12 months
2QFY2017 Result Update Pharmaceutical November 17, 2016 Sun Pharma Performance Highlights (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 7,764 8,007 (3.0) 6,858 13.2 Other income 621
More informationGeneric Pharmaceuticals Market A Global Analysis
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Generic Pharmaceuticals Market A Global Analysis VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market Research Reports
More information